Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

The incidence and prevalence of genital herpes simplex virus (HSV) type 1 and 2 infections are high worldwide, contr ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

Bangalore: Biocon has sold Eighty Lacs equity shares of Syngene International Limited for Rs. 686 crores. The transacted ...

Sweid One is a pivotal project for us, designed to raise the bar for commercial office space within JLT,” said Maher Sweid, ...

Bangalore), DKZP Higher Primary School Sandspit, Bengre (Mangalore) and ZPHS Moosapet (Hyderabad) triumph among 200 government schools • For the last ...

The arrest in the slaying of UnitedHealthcare CEO Brian Thompson was the first step to putting his killer behind bars, though ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Request To Download Sample of This Strategic Report@ Taiwan says China sending largest naval fleet in years to region Highlighted with 82 tables and 75 figures, this 197-page report ?North America ...

Global active pharmaceutical ingredients (API) market will reach $ 386.2 billion by 2032, growing by 6.4% annually over 2022-2032, driven by rising adoption of biologics in disease management, ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed yesterday at p1,341.00. Pick the ...